InsiderTrades

Form 4 for UTHR UNITED THERAPEUTICS Corp

Accepted 2022-07-08 00:00:00 ET · period of report 2022-07-07 · accession 0001415889-22-007600 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-07-08 2022-07-08 UTHR Olian Judy D. Dir M - OptEx $0.00 +2,160 10.4K +26% $0
D 2022-07-08 2022-07-08 UTHR Olian Judy D. Dir D - Sale to Iss $0.00 -2,160 0 -100% $0
D 2022-07-08 2022-07-07 UTHR Olian Judy D. Dir A - Grant $0.00 +1,750 1,750 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-07-08 M A 2,160 $0.00 10,390 D — — (F1) Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.
2 Derivative Restricted Stock Unit 2022-07-08 D D 2,160 $0.00 0 D $0.00 · 2022-07-08 to — 2,160 Common Stock (F2) Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. (F3) Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.
3 Derivative Restricted Stock Unit 2022-07-07 A A 1,750 $0.00 1,750 D $0.00 · 2023-07-07 to — 1,750 Common Stock (F4) Annual non-employee director award. (F2) Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. (F3) Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.